|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Neville BW and Day TA: Oral cancer and
precancerous lesions. CA Cancer J Clin. 52:195–215. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fusco A and Fedele M: Roles of HMGA
proteins in cancer. Nat Rev Cancer. 7:899–910. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Quan J, Johnson NW, Zhou G, Parsons PG,
Boyle GM and Gao J: Potential molecular targets for inhibiting bone
invasion by oral squamous cell carcinoma: A review of mechanisms.
Cancer Metastasis Rev. 31:209–219. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bella L, Zona S, Nestal de Moraes G and
Lam EW: FOXM1: A key oncofoetal transcription factor in health and
disease. Semin Cancer Biol. 29:32–39. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang Z, Ahmad A, Li Y, Banerjee S, Kong D
and Sarkar FH: Forkhead box M1 transcription factor: A novel target
for cancer therapy. Cancer Treat Rev. 36:151–156. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Halasi M and Gartel AL: FOX(M1) news-it is
cancer. Mol Cancer Ther. 12:245–254. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Leung TW, Lin SS, Tsang AC, Tong CS, Ching
JC, Leung WY, Gimlich R, Wong GG and Yao KM: Over-expression of
FoxM1 stimulates cyclin B1 expression. FEBS Lett. 507:59–66. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shi M, Cui J and Xie K: Signaling of
miRNAs-FOXM1 in cancer and potential targeted therapy. Curr Drug
Targets. 14:1192–1202. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang HG, Xu XW, Shi XP, Han BW, Li ZH,
Ren WH, Chen PJ, Lou YF, Li B and Luo XY: Overexpression of
forkhead box protein M1 (FOXM1) plays a critical role in colorectal
cancer. Clin Transl Oncol. 18:527–532. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dull T, Zufferey R, Kelly M, Mandel RJ,
Nguyen M, Trono D and Naldini L: A third-generation lentivirus
vector with a conditional packaging system. J Virol. 72:8463–8471.
1998.PubMed/NCBI
|
|
13
|
Korver W, Schilham MW, Moerer P, van den
Hoff MJ, Dam K, Lamers WH, Medema RH and Clevers H: Uncoupling of S
phase and mitosis in cardiomyocytes and hepatocytes lacking the
winged-helix transcription factor Trident. Curr Biol. 8:1327–1330.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jin H, Li XJ, Park MH and Kim SM:
FOXM1-mediated downregulation of uPA and MMP9 by
3,3′-diindolylmethane inhibits migration and invasion of human
colorectal cancer cells. Oncol Rep. 33:3171–3177. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Quan M, Wang P, Cui J, Gao Y and Xie K:
The roles of FOXM1 in pancreatic stem cells and carcinogenesis. Mol
Cancer. 12:1592013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhu H: Forkhead box transcription factors
in embryonic heart development and congenital heart disease. Life
Sci. 144:194–201. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gormally MV, Dexheimer TS, Marsico G,
Sanders DA, Lowe C, Matak-Vinković D, Michael S, Jadhav A, Rai G,
Maloney DJ, et al: Suppression of the FOXM1 transcriptional
programme via novel small molecule inhibition. Nat Commun.
5:51652014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chu XY, Zhu ZM, Chen LB, Wang JH, Su QS,
Yang JR, Lin Y, Xue LJ, Liu XB and Mo XB: FOXM1 expression
correlates with tumor invasion and a poor prognosis of colorectal
cancer. Acta Histochem. 114:755–762. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rao DD, Wang Z, Senzer N and Nemunaitis J:
RNA interference and personalized cancer therapy. Discov Med.
15:101–110. 2013.PubMed/NCBI
|
|
20
|
Swanton C, Nicke B and Downward J: RNA
interference, DNA methylation, and gene silencing: A bright future
for cancer therapy? Lancet Oncol. 5:653–654. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang Z, Rao DD, Senzer N and Nemunaitis J:
RNA interference and cancer therapy. Pharm Res. 28:2983–2995. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Root DE, Hacohen N, Hahn WC, Lander ES and
Sabatini DM: Genome-scale loss-of-function screening with a
lentiviral RNAi library. Nat Methods. 3:715–719. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kalin TV, Ustiyan V and Kalinichenko VV:
Multiple faces of FoxM1 transcription factor: Lessons from
transgenic mouse models. Cell Cycle. 10:396–405. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wakino S, Kintscher U, Kim S, Yin F, Hsueh
WA and Law RE: Peroxisome proliferator-activated receptor gamma
ligands inhibit retinoblastoma phosphorylation and G1->S
transition in vascular smooth muscle cells. J Biol Chem.
275:22435–22441. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu M, Dai B, Kang SH, Ban K, Huang FJ,
Lang FF, Aldape KD, Xie TX, Pelloski CE, Xie K, et al: FoxM1B is
overexpressed in human glioblastomas and critically regulates the
tumorigenicity of glioma cells. Cancer Res. 66:3593–3602. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rubin MA: Insights into the mechanism of
organ-specific cancer metastasis. Cancer Discov. 4:1262–1264. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kessenbrock K, Wang CY and Werb Z: Matrix
metalloproteinases in stem cell regulation and cancer. Matrix Biol.
44–46. 184–190. 2015.
|
